Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Roncalli

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Cancer|July 1, 1994
Prognostic value of N-myc immunoreactivity in medullary thyroid carcinomaM Roncalli, G Viale, L Grimelius, et al.
Breast (Edinburgh, Scotland)|August 18, 2009
Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapyI Garassino, G Gullo, S Orefice, et al.
The Journal of Pathology|February 1, 1991
Oncoprotein immunoreactivity in human endocrine tumoursM Roncalli, D R Springall, I M Varndell, et al.
Cancer|February 1, 1997
p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlationsG Coggi, S Bosari, M Roncalli, et al.
British Journal of Cancer|January 18, 2014
Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasiaA Malesci, G Basso, P Bianchi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 31, 2005
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlationsA Destro, G L Ceresoli, M Falleni, et al.
Lung Cancer (Amsterdam, Netherlands)|March 12, 2004
K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokersA Destro, P Bianchi, M Alloisio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancerA Santoro, R Cavina, F Latteri, et al.
British Journal of Cancer|October 6, 2011
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatinE Giovannetti, P A Zucali, Y G Assaraf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamideM Balzarotti, M Spina, B Sarina, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Cancer|July 1, 1994
Prognostic value of N-myc immunoreactivity in medullary thyroid carcinomaM Roncalli, G Viale, L Grimelius, et al.
Breast (Edinburgh, Scotland)|August 18, 2009
Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapyI Garassino, G Gullo, S Orefice, et al.
The Journal of Pathology|February 1, 1991
Oncoprotein immunoreactivity in human endocrine tumoursM Roncalli, D R Springall, I M Varndell, et al.
Cancer|February 1, 1997
p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlationsG Coggi, S Bosari, M Roncalli, et al.
British Journal of Cancer|January 18, 2014
Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasiaA Malesci, G Basso, P Bianchi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 31, 2005
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlationsA Destro, G L Ceresoli, M Falleni, et al.
Lung Cancer (Amsterdam, Netherlands)|March 12, 2004
K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokersA Destro, P Bianchi, M Alloisio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancerA Santoro, R Cavina, F Latteri, et al.
British Journal of Cancer|October 6, 2011
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatinE Giovannetti, P A Zucali, Y G Assaraf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamideM Balzarotti, M Spina, B Sarina, et al.
Pageof 8